Contact Matthew Banet
Title President


toSense markets CoVa 2, an FDA-cleared sensor shaped like a necklace: it is the world’s only body-worn device that measures vital signs and hemodynamic parameters (e.g. stroke volume, cardiac output, and fluids) all from a patient’s chest. Recent technological breakthroughs add measurements of blood pressure (cuffless) and pulse oximetry, also from the chest, to a new version of CoVa 2. A novel combination of miniaturized electrical, impedance, optical, and acoustic sensors makes these measurements. Released in 2019, this new product—CoVa Patch—is about the size of a business card and can be manufactured for under $100. 23 issued patents and roughly 50 pending patent applications protect it.

CoVa and CoVa Patch prevent decompensation in patients suffering from congestive heart failure and end-stage renal disease. These conditions affect, respectively, about 5.3 million and 600K Americans, resulting in annual healthcare costs estimated at $45 billion for CHF and $35 billion for ESRD.

toSense has executed sales contracts with top-5 medical device manufacturers in both the US and Japan to distribute its products, resulting in revenue bookings of more than $3M over the next 12 months. These partners, coupled with favorable 2019 reimbursement codes, will help the company market CoVa and CoVa Patch to hospitals, medical clinics, and patients at home.

Company News

Baxter Reports First-Quarter 2020 Results

DateApr 30, 2020
Acquired toSense, a California-based technology company focused on developing sensors and software for broad applications in non-invasive patient monitoring. toSense brings technology and expertise that is expected to be instrumental in Baxter’s development and launch of leading-edge monitoring innovations.
Read More →